Angelini Pharma secures exclusive global license rights to future identified drug targets
Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience
